Beeflow applies scientific knowledge and technologies to bee pollination. Providing professional pollination services to farmers increases crop yields while reducing bee population decline. Since first started 4 years ago in Argentina, the company has increased between 20-90% crop yields in Blueberries, Almonds, Raspberries, and Kiwifruit.
BioLumen is a nutritional technology company that develops a patented dietary fiber technology platform that reduces the negative effect of a diet heavy in processed foods. BioLumen's technology is composed of insoluble dietary fiber matrix covered with a blend of food ingredients created from the latest drug delivery system research. The company's product, a nutraceutical, focuses on high risk individuals with prediabetes to help manage blood sugar levels, protect their liver from excess sugar and feed their gut microbiome, delivering health benefits. BioLumen was founded on 2018 and is headquartered in San Francisco, California.
QuantumCyte is a technology platform company developing automated microdissection solutions for molecular pathology. Its automated tissue dissection system uses digital tissue maps to isolate ROIs that contain informative biomarkers for treatment decision support.
Helex uses its own genomics data, bioinformatics, and intelligent data-driven platform to create, verify, and distribute therapy-specific gRNAs. Founded in 2021 and is based in New York.
Helex uses its own genomics data, bioinformatics, and intelligent data-driven platform to create, verify, and distribute therapy-specific gRNAs. Founded in 2021 and is based in New York.
Rizlab Health enables practitioners and patients to acquire full blood count readings in minutes. Founded in 2018 and is based in East Princeton.
Rizlab Health enables practitioners and patients to acquire full blood count readings in minutes. Founded in 2018 and is based in East Princeton.
Filtricine, Inc. is a venture-backed, clinical stage biotech company based in Santa Clara, CA. We are developing a nutrient modulation platform which can identify metabolic vulnerabilities in cancers and exploit those vulnerabilities without the use of drugs.
Beeflow applies scientific knowledge and technologies to bee pollination. Providing professional pollination services to farmers increases crop yields while reducing bee population decline. Since first started 4 years ago in Argentina, the company has increased between 20-90% crop yields in Blueberries, Almonds, Raspberries, and Kiwifruit.
QuantumCyte is a technology platform company developing automated microdissection solutions for molecular pathology. Its automated tissue dissection system uses digital tissue maps to isolate ROIs that contain informative biomarkers for treatment decision support.
Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.
Prolific Machines is a biotech company developing cell technologies to redefine how cells are produced for a sustainable and healthy future. It combines cutting-edge technologies to enable cell production at a new scale. The company was founded in 2020 and is based in San Francisco, California.
Wayfinder Biosciences is a biotechnology company developing orally available small molecule drugs that modulate the function of the RNAs encoding key disease targets. The company's proprietary platform combines unique screening and computational technologies to rapidly discover potent, selective and biologically active RNA-targeting small molecules. Wayfinder's programs are focused on traditionally inaccessible targets in oncology and neurodegenerative disease. Wayfinder Biosciences was established in 2021 and is headquartered in Seattle, WA.
Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.
Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.
Mimio Health is a nutraceutical company focusing on the research and production of mimetic supplements. Its patent-pending fasting mimetic formulation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast.
Microgenesis offers a new fertility test and personalized nutritional supplementation that restores the fertility potential of women everywhere. Microgenesis has proven their validity in tough cases – women who have already failed multiple IVF implantations. Now, they are bringing their solution downmarket to OB-GYNs and D2C, operating out of a CLIA lab in Oakland. Microgenesis’ diagnostic detects subclinical inflammation that harms ovarian function and implantation. Their three-month treatment is drug-free and all-natural.
Powered by AI, EMBER is the mobile telehealth platform patients use to get better faster. EMBER connects you with a medical professional within minutes via private message or video call. Get the care that’s right for you—all in a simple, easy-to-use mobile app. Because affordable, personalized care starts before you get to the waiting room. Learn more at embermed.com.
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.
BioFeyn is improving what farmed fish eat. By optimizing marine ingredients so fish can get more of what they naturally get in the ocean, gains in efficiency and sustainability are improved across the industry. Through a specialized method of biodegradable nanoencapsulations, trace amounts of marine ingredients are surrounded by a shell of other naturally-derived compounds. This ensures better digestion, absorption, bioavailability, and delivery to target tissues in the animals to help them grow and remain healthy.
AsimicA focuses on developing novel technologies for improved production in Microbial Biosynthetic Factories. Their technologies have the potential for a multi-fold increase in yields of biosynthetic processes. Since relatively low yields of target products, made through the biosynthesis is the major limitation of biotechnology, our innovative approaches for production may revolutionize the industry. AsimicA was launched in November 2018, by Nikolai Mushnikov and Grant Bowman.
SyntheX expands the druggable proteome using synthetic biology-driven drug discovery platforms. The platforms rely on empirical intracellular selection to discover protein interaction modulators. These can discover compounds that disrupt a specific protein-protein interaction (PPI), or achieve the inverse, and bring an E3 ubiquitin ligase and a neosubstrate of interest together to achieve functional protein degradation. In addition to external discovery collaborations, the platforms have generated an internal oncology pipeline focused on unique mechanisms of action around genetically validated targets.
Liberum offers next generation protein manufacturing. Taking advantage of our suite of proprietary molecular and hardware technologies, we bring speed, scalability and cost reduction to disrupt current biologics manufacturing practices. Our vision is to democratize access to the fruits of synthetic biology.
Protera builds functional ingredients for the food industry using protein engineering and artificial intelligence. Their agency streamlines protein design and development with a proprietary deep-learning algorithm, to predict high-value protein products and enzymes with unprecedented speed, enabling customers to get healthy, safe foods made from ingredients that are produced responsibly and sustainably.
Getting drugs through the tumor barrier and across the blood brain barrier is a well-known, major challenge for medicine. Advanced Microbubbles uses tiny uniform bubbles, which are agitated with ultrasound at the site of a tumor, to open up the barriers so drugs can enter locally. Their bubbles can be delivered alongside the desired drug, or conjugated to many drugs.
Protera builds functional ingredients for the food industry using protein engineering and artificial intelligence. Their agency streamlines protein design and development with a proprietary deep-learning algorithm, to predict high-value protein products and enzymes with unprecedented speed, enabling customers to get healthy, safe foods made from ingredients that are produced responsibly and sustainably.
Membio's single-use 0.2-10 L benchtop bioreactor system uses a proprietary design to provide a constant environment for cells at all scales. One technique will provide the same outcomes at all scales, whether at 0.2 L, 10 L, or anywhere in between. Fully automated single-use bioreactors designed by the business to enable cost-effective and scalable manufacture.
Membio's single-use 0.2-10 L benchtop bioreactor system uses a proprietary design to provide a constant environment for cells at all scales. One technique will provide the same outcomes at all scales, whether at 0.2 L, 10 L, or anywhere in between. Fully automated single-use bioreactors designed by the business to enable cost-effective and scalable manufacture.
sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.
Membio's single-use 0.2-10 L benchtop bioreactor system uses a proprietary design to provide a constant environment for cells at all scales. One technique will provide the same outcomes at all scales, whether at 0.2 L, 10 L, or anywhere in between. Fully automated single-use bioreactors designed by the business to enable cost-effective and scalable manufacture.
BioROSA Technologies creates a biologically-based diagnostic standard of care for Autism Spectrum Disorders. The company was founded in 2018 and is based in Belmont, Massachusetts.
Dahlia Biosciences specializes in the fields of biotechnology and DNA analysis and diagnostics. The company provides a single-cell RNA analysis tools for research and diagnostic applications. Dahlia Biosciences was founded in 2011 and headquartered in California, United States.
sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.
Stämm Biotech specializes in life sciences. During the past two years, Stämm has designed a novel bioproduction system that leverages microfluidics, electroporation and robotics to solve the main constraint of the biotech industry: scaling up. Solving this problem could unlock a $700B market in the next 10 years. Today, after integrating these state-of-the-art technologies, the company is unveiling the future of biomanufacturing. Stämm downsized a whole biotech facility into an all-in-one, plug-n-play desktop unit: the Bioprocessor, which has proven to be at least 70x more productive than traditional bioreactors.
Precision Medicine for Infectious Diseases. Antibiotic Adjuvant is the only system designed to affect 90% of physician hospital antibiotic prescriptions, providing intelligent coordination of heretofore chaotic usage patterns. Antibiotic Adjuvant offers automated resistance control.
Beeline is an early-stage preclinical cell therapy company developing the next generation of immune cell therapies for immune-mediated human disease, particularly diseases which result from the patient's own immune cells attacking healthy tissue. We are genetically engineering a patient's own immune cells to secrete therapeutic proteins in vivo and induce tolerance. In particular, we are re-engineering Regulatory T cells (Tregs) to produce optimal quantities of immunomodulatory cytokines, antibodies, and other therapeutic proteins, and combining enhanced Treg function with antigen specificity via targeting receptors for improved localization.
BiomeSense is developing the first technology platform for continuous, at-home monitoring of the human gut microbiome, transforming the ability to understand & utilize the microbiome for precision medicine. The enabling technology is the GutLab, the first “smart bathroom” system for at-home microbiome monitoring, which is combined with the MetaBiome time-series analytics platform into a single end-to-end solution. The platform allows scientists, patients, and consumers the unprecedented ability to tie microbiome changes directly to clinical outcomes in real time, revolutionizing the ability to leverage the microbiome for better health.
11 Biomics is an early-stage, community-focused biotech company.
Dahlia Biosciences specializes in the fields of biotechnology and DNA analysis and diagnostics. The company provides a single-cell RNA analysis tools for research and diagnostic applications. Dahlia Biosciences was founded in 2011 and headquartered in California, United States.
Clinicai is building a smart toilet monitor for non-invasive early detection of gastrointestinal cancers and diseases.
Filtricine, Inc. is a venture-backed, clinical stage biotech company based in Santa Clara, CA. We are developing a nutrient modulation platform which can identify metabolic vulnerabilities in cancers and exploit those vulnerabilities without the use of drugs.
Nivien Therapeutics developed the first small molecule inhibitors of the Hippo signaling pathway. Read the Nivien story in The Washington Post: https://www.washingtonpost.com/national/health-science/heres-what-happened-when-i-tried-to-develop-a-new-drug-for-a-deadly-cancer/2019/01/11/
sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.
Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.
Stelvio Oncology is developing a personalized approach to glioblastoma treatment. Their team has core competencies of scientific creativity, clinical excellence and professional management required to successfully commercialize novel drug therapies and precision medicine diagnostics.
Health Linkages is the Data Provenance Company. It use blockchain-inspired technology to enable healthcare institutions to trust, protect and comfortably share their data.
Ravata is enabling production scale embryo engineering.
A2A Pharmaceuticals Inc. is a biotechnology company committed to the advancement of innovative scientific research and new therapeutic agents. Their focus is on the development of novel drugs to treat antibiotic resistant bacterial infections and address unmet needs in cancer. They incorporate computational tools and interdisciplinary ingenuity into the rational design of therapeutics. Their unique computational design platform SCULPT™ integrates experimentally determined target characteristics into the systematic construction of therapeutic candidates.
Ravata is enabling production scale embryo engineering.
Zika Virus, Dengue Fever, and other global pandemics ravish countries as a result of a lack of rapidly deployable field based diagnostics. mFluidX has created a DNA diagnostic test the size of a stick of gum that can be deployed and provide results in thirty minutes. All with a self-powered disposable chip that costs 1000x less than current bulky benchtop based lab diagnostics.
Headquartered in South San Francisco, Jungla is a biotechnology company delivering robust and scalable results for clinical genetic and genomic testing. To achieve this, Jungla develops and combines advances in functional genomics, computational biophysics, and computer science to proactively inform on the risk of variants in our genome. Jungla aims to empower clinical genetic testing with quantitative, model-driven guidance to complement and enhance observational data. Whereas existing solutions routinely used in the market have demonstrably poor accuracies, Jungla delivers robust, scalable, and auditable support with dramatically higher accuracies and increasingly mechanistic cellular and biophysical insights. We are supported by leading technology and healthcare investors.
Orphidia is developing a rapid blood diagnostic platform to simultaneously run common lab tests on a portable device.
Amino Labs is a biotechnology company that aims to make genetic engineering accessible to everyone. It works to enable the next industrial revolution of personalized manufacturing using biology and help solve the world's biggest problem from fuel to food to medicine. Driven by ground-breaking technology and UX, Amino Labs' easy-to-use kits are giving rise to the next 99 million bioengineers, from the ages of 8 and up. The company was founded in 2015 and is based in Lethbridge, Canada.
Orphidia is developing a rapid blood diagnostic platform to simultaneously run common lab tests on a portable device.
Making the next generation of performance BioFabrics.
Orphidia is developing a rapid blood diagnostic platform to simultaneously run common lab tests on a portable device.